The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| GPCR | +149.44% | N/A | N/A | +143% |
| S&P | +15.66% | +86.6% | +13.29% | +67% |
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company engaged in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in San Francisco, CA.
The company's investigational GLP-1 treatment performed admirably well in a phase 2b study.
We should know a lot more by year-end.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$978.29K | -266.2% |
| Market Cap | $1.61B | -35.8% |
| Market Cap / Employee | $7.39M | -56.4% |
| Employees | 218 | 47.3% |
| Net Income | -$65,798.87K | -92.1% |
| EBITDA | -$72,906.25K | -58.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $102.91M | -40.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $4.29M | 60.4% |
| Short Term Debt | $2.80M | 63.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -23.90% | -4.6% |
| Return On Invested Capital | -35.57% | 5.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$52,620.11K | -156.0% |
| Operating Free Cash Flow | -$51,045.27K | -156.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.73 | 1.15 | 1.45 | 2.09 | -23.40% |
| Price to Tangible Book Value | 1.73 | 1.15 | 1.45 | 2.09 | -23.40% |
| Enterprise Value to EBITDA | -14.97 | -2.93 | -5.94 | -11.60 | -66.69% |
| Return on Equity | -18.6% | -22.9% | -21.2% | -25.3% | 24.32% |
| Total Debt | $3.86M | $7.59M | $7.68M | $7.09M | 61.69% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
